Advertisement

Antimicrobial Resistance: Preventable or Inevitable?

Problem of the Era from Two Perspectives
  • Duygu Yazgan Aksoy
  • Mine Durusu Tanriover
  • Serhat Unal

Abstract

An antimicrobial agent is anything that inhibits microbial growth; unfortunately, introduction of a new antimicrobial agent is usually followed by the rapid emergence of resistance. Resistance can be intrinsic, which implies that not all species are intrinsically susceptible to all antimicrobials, or acquired depending on genetic or biochemical mechanisms used by the microorganism.

Keywords

Antimicrob Agent Methicillin Resistant Staphylococcus Aureus Nosocomial Pneumonia Acinetobacter Baumannii Clin Microbiol Infect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sefton AM. Mechanisms of antimicrobial resistance: Their clinical relevance in the new millennium. Drugs 2002;62:557–566.PubMedGoogle Scholar
  2. 2.
    Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis 1999;5:18–27.PubMedGoogle Scholar
  3. 3.
    Pieboji JG, Koulla-Shiro S, Ngassam P, Adiogo D, Njine T, Ndumbe P. Antimicrobial resistance of Gram-negative bacilli isolates from inpatients and outpatients at Yaounde Central Hospital, Cameroon. Int J Infect Dis 2004;8:147–154.PubMedGoogle Scholar
  4. 4.
    Cookson B. Infection and antimicrobial prescribing control in the new millennium: Nightmare or nirvana? J Clin Pathol 2000;53:66–70.PubMedGoogle Scholar
  5. 5.
    Gaynes RP. Surveillance of nosocomial infections: A fundamental ingredient for quality. Infect Control Hosp Epidemiol 1997;18:475–478.PubMedGoogle Scholar
  6. 6.
    Jarvis WR. Preventing the emergence of multidrug-resistant microorganisms through antimicrobial use controls: The complexity of the problem. Infect Control Hosp Epidemiol 1996;17:490–495.PubMedGoogle Scholar
  7. 7.
    Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975–1991. Infect Control Hosp Epidemiol 1992;13: 582–586.PubMedGoogle Scholar
  8. 8.
    Morris JG, Shay DK, Hebden JN et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin: Establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250–259.PubMedGoogle Scholar
  9. 9.
    Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996;275:234–240.PubMedGoogle Scholar
  10. 10.
    Centers for Disease Control and Prevention campaign to prevent antimicrobial resistance in health-care settings. MMWR 2002;51:343.Google Scholar
  11. 11.
    Alvarez-Lerma F, Palomar M, Grau S. Management of antimicrobial use in the intensive care unit. Drugs 2001;61:763–775.PubMedGoogle Scholar
  12. 12.
    Ruef C. Nosocomial infections in intensive care units. Infection 2005;3:105.Google Scholar
  13. 13.
    Foxman B, Barlow R, D’Arcy H, Gillespie B, Sobel JD. Urinary tract infection: Self-reported incidence and associated costs Ann Epidemiol 2000;10:509–515.Google Scholar
  14. 14.
    Urinary tract infections and the cost of antimicrobial resistance: A special report, in Roberts WO (ed). Postgraduate Medicine. Minneapolis, MN, Healthcare Information Programs, McGraw–Hill Healthcare Information Group, 2001.Google Scholar
  15. 15.
    Gordon KA, Jones RN. SENTRY Participant Groups (Europe, Latin America, North America). Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: Comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2003;45:295–301.PubMedGoogle Scholar
  16. 16.
    Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29:745–758.PubMedGoogle Scholar
  17. 17.
    Wright SW, Wrenn KD, Haynes ML. Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates. J Gen Intern Med 1999;14:606–609.PubMedGoogle Scholar
  18. 18.
    Miller LG, Tang AW. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin Proc 2004;79:1048–1053.PubMedGoogle Scholar
  19. 19.
    Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: A decision and cost analysis. Clin Infect Dis 2001;33:615–621.PubMedGoogle Scholar
  20. 20.
    Perfetto EM, Gondek K. Escherichia coli resistance in uncomplicated urinary tract infection: A model for determining when to change first-line empirical antibiotic choice. Manag Care Interface 2002;15:35–42.PubMedGoogle Scholar
  21. 21.
    Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA. The Sanford Guide to Antimicrobial Therapy, ed 34. Hyde Park, VT, Antimicrobial Therapy, Inc., 2004.Google Scholar
  22. 22.
    Muratani T, Matsumoto T. Bacterial resistance to antimicrobials in urinary isolates. Int J Antimicrob Agents 2004;24 Suppl 1:S28–S31.Google Scholar
  23. 23.
    Poiata A, Badicut I, Grigore L, Buiuc D. The frequency of in vitro resistance to fluoroquinolones among clinical isolates of Escherichia coli. Roum Arch Microbiol Immunol 2000;59: 63–69.PubMedGoogle Scholar
  24. 24.
    Andreu A, Alos JI, Goberdano M, Marco F, de la Rosa M, Garcia-Rodriguez JA. Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: A nationwide surveillance study. Enferm Infecc Microbiol Clin 2005;23:4–9.PubMedGoogle Scholar
  25. 25.
    Nicolle L. Best pharmacological practice: Urinary tract infections. Expert Opin Pharmacother 2003;4:693–704.PubMedGoogle Scholar
  26. 26.
    Kahlmeter G, Menday P, Cars O. Non-hospital antimicrobial usage and resistance in community acquired Escherichia coli urinary tract infection. J Antimicrob Chemother 2003;52:1005–1010.PubMedGoogle Scholar
  27. 27.
    Richard P, Delangle MH, Merrien D, et al. Fluoroquinolone use and fluoroquinolone resistance: Is there an association? Clin Infect Dis 1994;19:54–59.PubMedGoogle Scholar
  28. 28.
    Kresken M, Wiedemann B. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrob Agents Chemother 1988;32:1285–1288.PubMedGoogle Scholar
  29. 29.
    Muder RR, Brennen C, Goetz AM, Wagener MM, Rihs JD. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center. Antimicrob Agents Chemother 1991;35:256–258.PubMedGoogle Scholar
  30. 30.
    Pena C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995;39:520–524.PubMedGoogle Scholar
  31. 31.
    Nicolle LE. Urinary tract infection: Traditional pharmacologic therapies. Am J Med 2002;113(suppl 1A):35S–44S.PubMedGoogle Scholar
  32. 32.
    Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: A nationwide analysis. Clin Infect Dis 2001;33:89–94.PubMedGoogle Scholar
  33. 33.
    Aubert G, Levy PP, Ros A, Meley R, Bourge A, Dorche G. Changes in the sensitivity of urinary pathogens to quinolones between 1987 and 1990 in France. Eur J Clin Microbiol Infect Dis 1992;11:475–477.PubMedGoogle Scholar
  34. 34.
    Rüden H, Gastmeier P, Daschner FD, Schumacher M. Nosocomial and community-acquired infections in Germany. Summary of the results of first national prevalence study (NIDEP). Infection 1997;25:199–202.PubMedGoogle Scholar
  35. 35.
    Gastmeier P, Kampf G, Wischnewski N, et al. Prevalence of nosocomial infections in representative German hospitals. J Hosp Infect 1998;38:37–49.PubMedGoogle Scholar
  36. 36.
    Maki DG, Tambyah PA. Engineering out the risk of infection with urinary catheters. Emerg Infect Dis 2001;7:342–347.PubMedGoogle Scholar
  37. 37.
    Perrin M, Donnio PY, Heurtin-Lecorre C, Travert MF, Avril L. Comparative antimicrobial resistance and genomic diversity of Escherichia coli isolated from the urinary tract infections in the community and in hospitals. J Hosp Infect 1999:41;273–279.PubMedGoogle Scholar
  38. 38.
    Mathai D, Jones RN, Pfaller MA. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1510 hospitalized patients: A report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn Microbiol Infect Dis 2001;40:129–136.PubMedGoogle Scholar
  39. 39.
    Bouza E, San Juan R, Muñoz P, Voss A, Kluytmans J: Co-operative Group of the European Study Group on Nosocomial Infections. A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). European Study Group on Nosocomial Infections. Clin Microbiol Infect 2001;7:523–531.PubMedGoogle Scholar
  40. 40.
    Johansen TE. Nosocomially acquired urinary tract infections in urology departments. Why an international prevalence study is needed in urology. Int J Antimicrob Agents 2004;23(suppl 1):S30–S34.PubMedGoogle Scholar
  41. 41.
    Wagenlehner FM, Weidner W, Naber KG. Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamic considerations. J Hosp Infect 2005;60:191–200.PubMedGoogle Scholar
  42. 42.
    Morgan MA, Brock N, Schneider S, et al. β-Lactam resistance in Escherichia coli and Klebsiella pneumonia: Laboratory detection and patient characteristics [abstr], in: Program and Abstracts of 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, American Society for Microbiology, 1998, p 143.Google Scholar
  43. 43.
    Babni GS, Hall LMC, Yuamn M, et al. Changes in the epidemiology of Klebsiella species: ESBL producers collected from intensive care units in 1994 and 1997–1998 [abstr], in: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, American Society for Microbiology, 2000, p 122.Google Scholar
  44. 44.
    Einhorn AE, Neuhauser MM, Bearden DT, Quinn JP, Pendland SL. Extended-spectrum β-lactamases: Frequency, risk factors and outcomes. Pharmacotherapy 2002;22:14–20.PubMedGoogle Scholar
  45. 45.
    Rice LB. Successful interventions for gram-negative resistance to extended spectrum β-lactam antibiotics. Pharmacotherapy 1999;19:120S–128S.PubMedGoogle Scholar
  46. 46.
    Diekema DJ, Pfaller MA, Jones RA, et al. Survey of blood stream infections due to gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 1999;29:595–607.PubMedGoogle Scholar
  47. 47.
    D’Agata EM, Venkataraman L, DeGirolami P, et al. Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: Prevalence, risk factors, and rate of infection. Crit Care Med 1999;27:1090–1095.PubMedGoogle Scholar
  48. 48.
    Schiappa DA, Hayden MK, Matushek MG, et al. Ceftazidime resistant Klebsiella pneumonia and Escherichia coli bloodstream infection: A case control and molecular epidemiologic investigation. J Infect Dis 1996;174:529–536.PubMedGoogle Scholar
  49. 49.
    Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamase–producing Escherichia coli and Klebsiella pneumonia: Risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162–1171.PubMedGoogle Scholar
  50. 50.
    Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999;281:517–523.PubMedGoogle Scholar
  51. 51.
    Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum ?-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004;23:163–167.PubMedGoogle Scholar
  52. 52.
    Borer A, Gilad J, Menashe G, Peled N, Riesenberg K, Schlaeffer F. Extended-spectrum β-lactamase-producing Enterobacteriaceae strains in community-acquired bacteremia in southern Israel. Med Sci Monitor 2002;8:CR44–CR7.Google Scholar
  53. 53.
    Munday CJ, Whitehead GM, Todd NJ, Campbell M, Hawkey PM. Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum β-lactamases in York, UK. J Antimicrobiol Chemother 2004;54:628–633.Google Scholar
  54. 54.
    Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ, for the Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347–382.PubMedGoogle Scholar
  55. 55.
    Niederman MS, Mandell LA, Anzueto A, et al, for the Ad-hoc Sub-committee of the assembly on microbiology, tuberculosis and pulmonary infections. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730–1754.PubMedGoogle Scholar
  56. 56.
    Sahm DF. Resistance issues and community-acquired respiratory infections. Clin Cornerstone 2003;Suppl 3:S4–S11.PubMedGoogle Scholar
  57. 57.
    Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000; 90: 223–229.PubMedGoogle Scholar
  58. 58.
    Cross JT Jr, Campbell GD Jr. Drug-resistant pathogens in community- and hospital-acquired pneumonia. Clin Chest Med 1999;20:499–506.PubMedGoogle Scholar
  59. 59.
    Whitney CG, Farley MM, Hadler J, et al. Active Bacterial Core Surveillance program of the Emerging Infections Program Network. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917–1924.PubMedGoogle Scholar
  60. 60.
    Baquero F. Pneumococcal resistance to beta-lactam antibiotics: A global geographic overview. Microb Drug Resist 1995;1:115–120.PubMedGoogle Scholar
  61. 61.
    Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399–1408.PubMedGoogle Scholar
  62. 62.
    Doern GV, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998; 27:764–770.PubMedGoogle Scholar
  63. 63.
    Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med 2005;118 Suppl 7A:21S–28S.PubMedGoogle Scholar
  64. 64.
    Jones RN, Mandell LA. Fluoroquinolones for the treatment of outpatient community-acquired pneumonia. Diagn Microbiol Infect Dis 2002;44:69–76.PubMedGoogle Scholar
  65. 65.
    Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: Have we begun to turn corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005;41:139–149.PubMedGoogle Scholar
  66. 66.
    Abdel-Rahman EM, Ismael NA, Dixon RA. Antibiotic resistance and prevalence of β-lactamase in Haemophilus influenza isolates—A surveillance study of patients with respiratory infection in Saudi Arabia. Diagn Microbiol Infect Dis 2000;36:203–208.PubMedGoogle Scholar
  67. 67.
    Doern GV, Pfaller MA, Erwin ME, Brueggemann AB, Jones RN. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada—1997 results from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 1998; 32:313–316.PubMedGoogle Scholar
  68. 68.
    Brown SD, Rybak MJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001–2002, as part of the PROTEKT US study. J Antimicrob Chemother 2004;54 Supp1:i7–i15.Google Scholar
  69. 69.
    Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Rice CL, Doern GV. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis 2005;40:225–235.PubMedGoogle Scholar
  70. 70.
    Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn Microbiol Infect Dis 2005;51:31–37.PubMedGoogle Scholar
  71. 71.
    Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997; 112(6 Suppl):310S–313S.PubMedGoogle Scholar
  72. 72.
    Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: Relation between bacteriologic etiology and lung infection. Chest 1998;113:1542–1548.PubMedGoogle Scholar
  73. 73.
    Pfaller MA, Ehrhardt AF, Jones RN. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory infections in the respiratory surveillance program study: Microbiology from the medical office practice environment. Am J Med 2001;111 Suppl 9A:4S–12S.PubMedGoogle Scholar
  74. 74.
    Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patient with pulmonary infiltrates in the intensive care unit: A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000;162:505–511.PubMedGoogle Scholar
  75. 75.
    McEachern R, Campbell GD Jr. Hospital-acquired pneumonia: Epidemiology, etiology, and treatment. Infect Dis Clin North Am 1998;12:761–779.PubMedGoogle Scholar
  76. 76.
    American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator associated, and health-care associated pneumonia. Am J Respir Crit Care Med 2005;171:388–416.Google Scholar
  77. 77.
    Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: A randomized trial. JAMA 2000;283:1583–1590.PubMedGoogle Scholar
  78. 78.
    Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003; 362:887–899.PubMedGoogle Scholar
  79. 79.
    Espinal MA. The global situation of MDR-TB. Tuberculosis 2003;83:44–51.PubMedGoogle Scholar
  80. 80.
    Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—worldwide, 2000–2004. MMWR 2006;55:301–305.Google Scholar
  81. 81.
    Pablos-Mendez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis drug resistance, 1994–1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998;338:1641–1649.PubMedGoogle Scholar
  82. 82.
    Di Perri G, Bonora S. Which agents should we use for the treatment of multidrugresistant Mycobacterium tuberculosis? J Antimicrob Chemother 2004;54:593–602.PubMedGoogle Scholar
  83. 83.
    Lalloo UG, Naidoo R, Ambaram A. Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis. Curr Opin Pulm Med 2006;12:179–185.PubMedGoogle Scholar
  84. 84.
    Diekema DJ, Pfaller MA, Schmitz FJ, et al. and the SENTRY participants. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Wertern Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 2001;32 Suppl 2:S114–S132.PubMedGoogle Scholar
  85. 85.
    Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867–903.PubMedGoogle Scholar
  86. 86.
    Shorr AF, Combes A, Kollef MH, Chastre J. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 2006;34:700–706.PubMedGoogle Scholar
  87. 87.
    Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother 1994;38:2231–2237.PubMedGoogle Scholar
  88. 88.
    Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339: 20–32.Google Scholar
  89. 89.
    National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992–June 2001, issued August 2001. Am J Infect Control 2001; 29:404–421.Google Scholar
  90. 90.
    Barber M. Methicillin resistant staphylococci. J Clin Pathol 1961;14;385–393.PubMedGoogle Scholar
  91. 91.
    Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309–317.PubMedGoogle Scholar
  92. 92.
    Ho M, McDonald LC, Lauderdale TL, et al. Surveillance of antibiotic resistance in Taiwan, 1998. J Microbiol Immunol Infect 1999;32:239–249.PubMedGoogle Scholar
  93. 93.
    Brumfitt W, Hamilton-Miller J. Methicillin resistant Staphylococcus aureus. N Engl J Med 1989;320:1188–1196.PubMedCrossRefGoogle Scholar
  94. 94.
    Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carnelli Y. Comparison of mortality associated with methicillin-resistant and methicillin susceptible Staphylococcus aureus bacteremia: A meta analysis. Clin Infect Dis 2003;36:53–59.PubMedGoogle Scholar
  95. 95.
    Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteremia: A meta-analysis. Med J Aust 2001;175:264–267.PubMedGoogle Scholar
  96. 96.
    Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135–136.PubMedGoogle Scholar
  97. 97.
    Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:517–523.PubMedGoogle Scholar
  98. 98.
    Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin resistant Staphylococcus aureus. Clin Microbiol Infect 2006;12 Suppl 1:16–23.Google Scholar
  99. 99.
    Segreti J. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance. Clin Microbiol Infect 2005;11:29–35.PubMedGoogle Scholar
  100. 100.
    Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207–208.PubMedGoogle Scholar
  101. 101.
    Verhoef J, Beaujean D, Blok H, et al. A Dutch approach to methicillin resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1999;18:461–466.PubMedGoogle Scholar
  102. 102.
    Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current microbial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrobiol 2006;5:2.Google Scholar
  103. 103.
    Centers for Disease Control. Community-acquired methicillin-resistant Staphylococcus aureus infections: Michigan. MMWR 1981;30:185–187.Google Scholar
  104. 104.
    Saravolatz LD, Pohlod DJ, Arking LM. Community-acquired methicillin-resistant Staphylococcus aureus infections: A new source for nosocomial outbreaks. Ann Intern Med 1982;97:325–329.PubMedGoogle Scholar
  105. 105.
    From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus—Minnesota and North Dakota, 1997–1999. JAMA 1999;282:1123–1125.Google Scholar
  106. 106.
  107. 107.
    Murray RJ, Lim TT, Pearson JC, Grubb WB, Lum GD. Community-onset methicillin resistant Staphylococcus aureus bacteremia in northern Australia. Int J Infect Dis 2004;8:275–283.PubMedGoogle Scholar
  108. 108.
    Hidron AI, Kourbatova E, Halvosa JS, et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: Emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005;41:159–166.PubMedGoogle Scholar
  109. 109.
    Rezende NA, Blumberg HM, Metzger BS, Larsen NM, Ray SM, McGowan JE Jr. Risk factors for methicillin-resistance among patients with Staphylococcus aureus bacteremia at the time of hospital admission. Am J Med Sci 2002; 323: 117–123.PubMedGoogle Scholar
  110. 110.
    Calfee DP, Durbin LJ, Germanson TP, Toney DM, Smith EB, Farr BM. Spread of methicillin resistant Staphylococcus aureus (MRSA) among household contacts of individuals with nosocomially acquired MRSA. Infect Control Hosp Epidemiol 2003;24:422–426.PubMedGoogle Scholar
  111. 111.
    Maltezou HC, Giamarellou H. Community-acquired methicillin-resistant Staphylococcus aureus infections. Int J Antimicrob Agents 2006;27:87–96.PubMedGoogle Scholar
  112. 112.
    Anonymous. National Nosocomial Infections Surveillance (NNIS) System Report: Data summary from October 1986 to April 1998, issued June 1998. Am J Infect Control 1988;26:522–533.Google Scholar
  113. 113.
    Anonymous. National Nosocomial Infections Surveillance (NNIS) Report, data summary from October 1986 to April 1996, issued May 1996. Am J Infect Control 1996;24:380–388.Google Scholar
  114. 114.
    Bouza E, Burillo A, Munoz P. Catheter-related infections: Diagnosis and intravascular treatment. Clin Microbiol Infect 2002;8:265–274.PubMedGoogle Scholar
  115. 115.
    Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274:639–644.PubMedGoogle Scholar
  116. 116.
    Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996;109:1019–1029.Google Scholar
  117. 117.
    Mayhall CG. Nosocomial pneumonia. Diagnosis and prevention. Infect Dis Clin North Am 1997;11:427–457.PubMedGoogle Scholar
  118. 118.
    Rello J, Rue M, Jubert P, et al. Survival in patients with nosocomial pneumonia: Impact of the severity of illness and the etiologic agent. Crit Care Med 1997;25:1862–1867.PubMedGoogle Scholar
  119. 119.
    Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985;145:1621–1629.PubMedGoogle Scholar
  120. 120.
    Gallagher PG, Watanakunakorn C. Pseudomonas bacteremia in a community teaching hospital 1980–1984. Rev Infect Dis 1989;11:846–852.PubMedGoogle Scholar
  121. 121.
    Siegman-Igra Y, Ravona R, Primerman H, Giladi M. Pseudomonas aeruginosa bacteremia: An analysis of 123 episodes, with particular emphasis on the effect of antimicrobial therapy. Int J Infect Dis 1998;2:211–215.PubMedGoogle Scholar
  122. 122.
    Pollack M. Pseudomonas aeruginosa, in Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases, ed 5. Philadelphia, Churchill Livingstone, 2000, pp 2310–2335.Google Scholar
  123. 123.
    Koll BS, Brown AE. The changing epidemiology of infections at cancer hospitals. Clin Infect Dis 1993;17 Suppl 2:S322-S328.PubMedGoogle Scholar
  124. 124.
    Aquino VM, Pappo A, Buchanan GR, Tkaczewski I, Mustafa MM. The changing epidemiology of bacteremia in neutropenic children with cancer. Pediatr Infect Dis J 1995;14:140–143.PubMedCrossRefGoogle Scholar
  125. 125.
    Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741–1751.PubMedGoogle Scholar
  126. 126.
    Pizzo PA. Fever in immunocompromised patients. N Engl J Med 1999;341:893–900.PubMedGoogle Scholar
  127. 127.
    Giamarellou H, Antoniadou A. Antipseudomonal antibiotics. Med Clin North Am 2001;85:19–42.PubMedGoogle Scholar
  128. 128.
    Jones RN, Beach ML, Pfaller MA. Spectrum and activity of the three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from the urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas: 2000): More alike than different! Diagn Microbiol Infect Dis 2001;41:161–163.PubMedGoogle Scholar
  129. 129.
    Giamarellou H. Prescribing guidelines for severe Pseudomonas infections. J Antimicrob Chemother 2002;49:229–233.PubMedGoogle Scholar
  130. 130.
    Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU settings. Chest 2000;118: 146–155.PubMedGoogle Scholar
  131. 131.
    Jones RN, Kirby JT, Beach ML, Biedenbach DJ, Pfaller MA. Geographic variations in activity of broad spectrum ?-lactams against Pseudomonas aeruginosa: Summary of worldwide SENTRY antimicrobial surveillance program (1997–2000). Diagn Microbiol Infect Dis 2002;43:239–243.PubMedGoogle Scholar
  132. 132.
    Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from the hospitalized patients in the United States, 1998–2001. Antimicrob Agents Chemother 2003;47:1681–1688.PubMedGoogle Scholar
  133. 133.
    Mendes C, Turner PJ. MYSTIC Study Group (Europe). Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997–2000). Diagn Microbiol Infect Dis 2001;41:191–196.PubMedGoogle Scholar
  134. 134.
    Hanberger H, Diekema D, Fluit A et al. Surveillance of antibiotic resistance in European ICUs. J Hosp Infect 2001;48:161–176.PubMedGoogle Scholar
  135. 135.
    Friedland I, Stinson L, Ikaiddi M, Harm S, Woods GL. Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter: Results of a Multicenter Intensive Care Unit Surveillance Study, 1995–2000. Diagn Microbiol Infect Dis 2003;45:245–250.PubMedGoogle Scholar
  136. 136.
    Pfaller MA, Jones RN, Biedenbach DJ. MYSTIC Program Study Group. Antimicrobial resistance trends in medical centers using carbapenems: Report of 1999 and 2000 results from the MYSTIC Program (USA). Diagn Microbiol Infect Dis 2001;41:177–182.PubMedGoogle Scholar
  137. 137.
    Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 2001;32 Suppl 2:S146–S155.PubMedGoogle Scholar
  138. 138.
    Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin Infect Dis 2002;34:634–640.PubMedGoogle Scholar
  139. 139.
    Wang CY, Jerng JS, Cheng KY, et al. Pandrug-resistant Pseudomonas aeruginosa among hospitalized patients: Clinical features, risk factors and outcomes. Clin Microbiol Infect 2006;12:63–68.PubMedGoogle Scholar
  140. 140.
    Zeana C, Larson E, Sahni J, Bayuga SJ, Wu F, Della-Latta P. The epidemiology of multidrug-resistant Acinetobacter baumannii: Does the community represent a reservoir? Infect Control Hosp Epidemiol 2003;24:275–279.PubMedGoogle Scholar
  141. 141.
    Maslow JN, Glaze T, Adams P, Lataillade M. Concurrent outbreak of multidrug resistant and susceptible subclones of Acinetobacter baumannii affecting different wards of a single hospital. Infect Control Hosp Epidemiol 2005;26:69–75.PubMedGoogle Scholar
  142. 142.
    Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994: 344: 1329–1332.PubMedGoogle Scholar
  143. 143.
    D’Agata EM, Thayer V, Schaffner W. Outbreak of Acinetobacter baumannii: The importance of cross-transmission. Infect Control Hosp Epidemiol 2000;21:588–591.PubMedGoogle Scholar
  144. 144.
    Husni RN, Goldstein LS, Arroliga AC, et al. Risk factors for an outbreak of multi-drug resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest 1999;115:1378–1382.PubMedGoogle Scholar
  145. 145.
    Cox TR, Roland WE, Dolan ME. Ventilator related Acinetobacter outbreak in an intensive care unit. Mil Med 1998;163:389–391.PubMedGoogle Scholar
  146. 146.
    Roberts SA, Findlay R, Lang SD. Investigation of an outbreak of multi-drug resistant Acinetobacter baumannii in an intensive care burns unit. J Hosp Infect 2001; 48:228–232.PubMedGoogle Scholar
  147. 147.
    Neely AN, Maley MP, Warden GD. Computer keyboards as reservoirs for Acinetobacter baumannii in a burn hospital. Clin Infect Dis 1999;29:1358–1360.PubMedGoogle Scholar
  148. 148.
    Manikal VM, Landman D, Saurina G, Odyna E, Lal H, Quale J. Endemic carbapenemresistant Acinetobacter species in Brooklyn, New York: City prevalence, interinstitutional spread, and relation to antibiotic use. Clin Infect Dis 2000:31:101–106.PubMedGoogle Scholar
  149. 149.
    Rahal JJ, Urban C, Segal-Maurer S. Nosocomial antibiotic resistance in multiple gram-negative species: Experience at one hospital with squeezing the resistance balloon at multiple sites. Clin Infect Dis 2002;34:499–503.PubMedGoogle Scholar
  150. 150.
    Dijkshoorn L, Aucken H, Gerner-Smidt P, et al. Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. J Clin Microbiol 1996;34:1519–1525.PubMedGoogle Scholar
  151. 151.
    Cisneros JM, Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: Epidemiology, clinical features and treatment. Clin Microbiol Infect 2002;8:687–693.PubMedGoogle Scholar
  152. 152.
    Cawley MJ, Suh C, Lee S, Ackerman BH. Nontraditional dosing of ampicillinsulbactam for multidrug resistant Acinetobacter baumannii meningitis. Pharmacotherapy 2002;22:527–532.PubMedGoogle Scholar
  153. 153.
    Nikolaidis P, Metallidis S, Kollaras P, Tsona A, Koumedaki E, Tsaousoglu D. In vitro activity of clinafloxacin compared to ciprofloxacin against Acinetobacter baumannii strains isolated from intensive care unit patients. J Chemother 2002;14:234–236.PubMedGoogle Scholar
  154. 154.
    Fung-Tomc JC, Gradelski E, Valera L, Huczko E, Bonner DP. Synergistic activity of the novel des-fluoro(6) quinolone garenfloxacin (BMS-284756) in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species. Int J Antimicrob Agents 2002;20:57–60.PubMedGoogle Scholar
  155. 155.
    Jellison TK, McKinnon PS, Rybak MJ. Epidemiology, resistance and outcome of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillinsulbactam. Pharmacotherapy 2001;21:142–148.PubMedGoogle Scholar
  156. 156.
    Barisic Z, Punda-Polic V. Antibiotic resistance among enterococcal strains isolated from clinical specimens. Int J Antimicrob Agents 2000;16:65–68.PubMedGoogle Scholar
  157. 157.
    Chavers LS, Moser SA, Benjamin WH, et al. Vancomycin-resistant enterococci: 15 years and counting. J Hosp Infect 2003;53:159–171.PubMedGoogle Scholar
  158. 158.
    Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342:710–721.PubMedGoogle Scholar
  159. 159.
    Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663–670.PubMedGoogle Scholar
  160. 160.
    Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin resistant Enterococcus in a level 1 trauma center. Clin Infect Dis 2002;34:922–929.PubMedGoogle Scholar
  161. 161.
    Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: Does vancomycin resistance make a difference? Arch Intern Med 1998;158:522–527.PubMedGoogle Scholar
  162. 162.
    Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug resistant Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003;24:362–386.PubMedGoogle Scholar
  163. 163.
    Lee TA, Hacek DM, Stroupe KT, Collins SM, Peterson LR. Three surveillance strategies for vancomycin-resistant enterococci in hospitalized patients: Detection of colonization efficiency and a cost-effectiveness model. Infect Control Hosp Epidemiol 2005;26:39–46.PubMedGoogle Scholar
  164. 164.
    Holloway K. Antimicrobial resistance: The facts. Essential Drug Monitor, WHO 2000;28–29:7–8.Google Scholar
  165. 165.
    Sharma R, Sharma CL, Kapoor B. Antibacterial resistance: Current problems and possible solutions. Indian J Med Sci 2005;59:120–129.PubMedGoogle Scholar
  166. 166.
    Appelbaum PC, Gillespie SH, Burley CJ, Tillotson GS. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21stcentury: A review of gemifloxacin. Int J Antimicrob Agents 2004;23:533–546.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Duygu Yazgan Aksoy
    • 1
  • Mine Durusu Tanriover
    • 1
  • Serhat Unal
    • 2
  1. 1.Department of MedicineHacettepe University Faculty of MedicineAnkaraTurkey
  2. 2.Department of Medicine, Section of Infectious DiseasesHacettepe University Faculty of MedicineAnkaraTurkey

Personalised recommendations